Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | STAMBP | O95630 | 4/20 | 0.38 |
| ▸ | COPS5 | Q92905 | 2/20 | 0.38 |
| ▸ | PSMD14 | O00487 | 3/20 | 0.36 |
| ▸ | CFTR | P13569 | 7/20 | 0.36 |
| ▸ | ULK1 | O75385 | 2/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.34 |
| ▸ | NAMPT | P43490 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6986734 | 0.72 | CA2 (0.31) | CA2STAMBPCOPS5PSMD14 | |
| SCHEMBL6983110 | 0.68 | GABRA5 (0.32) | STAMBP | |
| SCHEMBL6383909 | 0.68 | PTGS1 (0.48) | CA2 | |
| SCHEMBL2305220 | 0.67 | CA2 (0.44) | CA2CFTRULK1NAMPT | |
| SCHEMBL22059413 | 0.66 | STAMBP (0.51) | STAMBPCOPS5PSMD14ULK1 | |
| SCHEMBL6985100 | 0.65 | MEN1 (0.35) | CA2 | |
| SCHEMBL6386895 | 0.65 | PTGS1 (0.50) | — | |
| SCHEMBL6577234 | 0.63 | LOXL2 (0.53) | CA2ULK1 | |
| SCHEMBL24869259 | 0.61 | CFTR (0.41) | CA2CFTR | |
| SCHEMBL6579452 | 0.61 | CA2 (0.40) | CA2PSMD14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1027351-B1 | PHENANTHROLINE DERIVATIVES | FIBROGEN INC (US) | 2003-12-03 | — | — | EP | disclosed |
| US-20010001101-A1 | Phenanthroline derivatives | ZENECA LIMITED | 2001-05-10 | — | — | US | disclosed |
| US-6200974-B1 | FOR PRODUCING AN ANTI-FIBROPROLIFERATIVE EFFECT | ZENECA LIMITED (GB) | 2001-03-13 | — | — | US | disclosed |
| EP-1027351-A1 | PHENANTHROLINE DERIVATIVES | FIBROGEN, INC. (US) | 2000-08-16 | — | — | EP | disclosed |
| WO-1999021860-A1 | PHENANTHROLINE DERIVATIVES | FIBROGEN, INC. (US) | 1999-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010001101-A1 | Phenanthroline derivatives | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, COL1A1, COL2A1 | CA2 29/4885STAMBP 4323/4885COPS5 2086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.